Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:28 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 251 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Healthy Adult Males Clear all

Conditions: Healthy
Interventions: TS-121, [11C]TASP0410699, Positron Emission Tomography (PET); Drug · Radiation
Lead sponsor: Taisho Pharmaceutical R&D Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Erectile Dysfunction
Interventions: ASP-001.1, ASP-001, Commercial Sildenafil and Sildenafil/Tadalafil Products; Device · Drug
Lead sponsor: Aspargo Labs, Inc; Industry
Eligibility: 18 Years to 70 Years · Male only
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Hyperuricemia, Gout, Qt Interval, Variation in
Interventions: LC350189 200mg, Placebo, Moxifloxacin 400mg, LC350189 600mg; Drug
Lead sponsor: LG Chem; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy
Interventions: DEPAKOTE® Tablets, 500 MG, DIVALPROEX SODIUM DELAYED-RELEASE TABLETS, USP, 500 MG; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Healthy
Interventions: Decitabine, Tetrahydrouridine; Drug
Lead sponsor: EpiDestiny, Inc.; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Drug-drug Interaction
Interventions: HBI-3000, Paroxetine; Drug
Lead sponsor: HUYABIO International, LLC.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Diabetes Mellitus, Type 2
Interventions: GSK716155 subcutaneous injections; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 6
States / cities: Long Beach, California • Walnut Creek, California • Miramar, Florida + 3 more

Conditions: Staphylococcus Aureus
Interventions: AZD7760, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 242 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 40
States / cities: Huntsville, Alabama • Chula Vista, California • Glendale, California + 35 more

Conditions: Fever
Interventions: IV Placebo, IV Acetaminophen, Reference Standard Endotoxin (RSE); Drug · Biological
Lead sponsor: Mallinckrodt; Industry
Eligibility: 18 Years to 75 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Obstetric Labour, Premature, Premature Ejaculation
Interventions: GSK221149; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2007
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Healthy
Interventions: Not listed
Lead sponsor: Topcon Corporation; Industry
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 6
States / cities: La Jolla, California • Overland Park, Kansas • New York, New York + 1 more

Conditions: ADME, Healthy
Interventions: napabucasin; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Hepatitis B
Interventions: Bepirovirsen; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: Orlando, Florida • Tampa, Florida • San Antonio, Texas

Conditions: Healthy
Interventions: PF-07265803; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Anxiety Disorders
Interventions: d-cycloserine and mifepristone; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Healthy Adult Male
Interventions: Multi-ingredient preworkout supplement; Dietary Supplement
Lead sponsor: Northern Illinois University; Other
Eligibility: 19 Years to 29 Years · Male only
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: DeKalb, Illinois

Conditions: Encephalitis
Interventions: AVI-4065 Injection; Drug
Lead sponsor: Sarepta Therapeutics, Inc.; Industry
Eligibility: 18 Years to 64 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Healthy
Interventions: PA21 and Omeprazole with food, No PA21; Omeprazole with food, PA21 with food, Omeprazole 2hrs later; Drug
Lead sponsor: Vifor Pharma; Industry
Eligibility: 20 Years to 50 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Healthy Volunteers
Interventions: TAK-935 Oral Tablet, [14C]TAK-935 IV Infusion, [14C]TAK-935 Oral Solution; Drug
Lead sponsor: Takeda; Industry
Eligibility: 19 Years to 55 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Healthy
Interventions: Lesinurad 400 mg, Tums 500 mg and 750 mg, MINTOX 10 mL; Drug
Lead sponsor: Ardea Biosciences, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Kalamazoo, Michigan

Conditions: Healthy
Interventions: Nirogacestat, Nirogacestat and Famotidine, Nirogacestat and Rabeprazole; Drug
Lead sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Healthy Volunteers
Interventions: [14C]-CTP-543; Drug
Lead sponsor: Concert Pharmaceuticals; Industry
Eligibility: 19 Years to 55 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Human Volunteers
Interventions: BMN 673; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: West Nile Virus
Interventions: AVI-4020 Injection; Drug
Lead sponsor: Sarepta Therapeutics, Inc.; Industry
Eligibility: 18 Years to 64 Years · Male only
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Tacoma, Washington

Search by objective public record fields.

Exploratory Study Using Positron Emission Tomography With TS-121 and [11C]TASP0410699 in Healthy Adult Male Subjects

Hezkue®, Hezkue Turbo®, and Commercial Sildenafil Products in Fed Healthy Male Subject

Thorough QT (TQT) Study to Evaluate the Effect of LC350189 on Cardiac Repolarization in Healthy Male and Female Subjects

Bioequivalence Study of Divalproex Sodium Delayed-Release Tablets, 500 mg

To Study the Oral Bioavailability of a New Combination Formation of Decitabine and Tetrahydrouridine in Healthy Males

Drug-Drug Interaction Study of HBI-3000 and Paroxetine in Healthy Adult Male and Female Subjects

Injection Site Study In Patients With Type 2 Diabetes Mellitus (T2DM) And Healthy Volunteers

A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)

Safety of Intravenous Acetaminophen Vs Placebo for the Treatment of Endotoxin-Induced Fever in Healthy Adult Males

A Study To Assess The Pharmacokinetics Of Different Modified Release Formulations Of GSK221149 In Healthy Adult Subjects

An Age-Stratified Data Collection Study to Establish a Normative Database Using the 3D Optical Coherence Tomography 3D OCT-1000 Mark II

A Study to Evaluate the Mass Balance of 14C-Napabucasin in Healthy Adult Male Subjects

A Study to Evaluate Blood Levels of Bepirovirsen in Adult Participants With Severe or Moderate Kidney Disease

A Study To Evaluate The Pharmacokinetics, Excretion, Mass Balance and Metabolism of PF-07265803

Medication Enhanced Rapid Therapy

Multi-Ingredient Preworkout Supplement on Peak Torque and Muscle Activation During Fatigue

Pharmacokinetic Study of a Single Dose of AVI-4065 in Cerebral Spinal Fluid

A Drug-Drug Interaction Study of Omeprazole and PA21

Study to Assess Absolute Bioavailability of TAK-935 (OV935) and to Characterize Mass Balance, Pharmacokinetics, Metabolism, and Excretion of [14C]TAK-935 (OV935) in Healthy Male Participants

Antacid Interaction Study

Evaluate the Effects of Famotidine or Rabeprazole on the PK of Nirogacestat

Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers

Study of BMN 673, a PARP Inhibitor, in Healthy Adult Male Volunteers

Pharmacokinetic Study in Cerebral Spinal Fluid After a Single Dose of AVI-4020